SorbaView® SHIELD

Try the integrated all-in-one central line dressing and securement device.
A clinician secures the catheter hub in SorbaView SHIELD device she’s put on a patient’s arm.
A clinician secures the catheter hub in SorbaView SHIELD device she’s put on a patient’s arm.
PRODUCT BENEFITS

Help reduce CLABSI rates and related costs

SorbaView SHIELD is a multi-layer, all-in-one dressing and catheter securement device that helps protect patients from central line-associated bloodstream infections and complications like phlebitis, extravasation and infiltration. The innovative design shields the insertion site and keeps the catheter securely in place. It also eliminates the cost of a secondary securement device.
Stat says patient mortality is up to 25% for patients with a CLABSI.

Readmittance is 5x more likely

for patients with a CLABSI1
Stat says patient mortality is up to 25% for patients with a CLABSI.

Patient mortality is up to 25%

for patients with a CLABSI2
how it works

Explore the advantages of one-step protection and securement

SorbaView SHIELD protects and secures the catheter throughout the life of the line, preventing CVC dislodgement, unscheduled IV restarts and dressing disruptions.
  • Multiple layers form a breathable film barrier to infectious bacteria
  • SHIELD technology resists all-angles tugging forces from patient movement and repositioning
  • Reinforced collar locks hubs firmly in place
  • Large window makes it easy to assess the insertion site
  • Holds central lines in place up to 7 days and peripherals up to 96 hours
EVIDENCE-BASED PRACTICES

INS guidelines recommend integrated securement products

The most current Infusion Nurses Society (INS) Standards of Practice state that inadequate vascular access device securement creates the risk for complications that could result in premature device removal.3 SorbaView SHIELD keeps the dressing and catheter secure to help reduce infection risk.
Statistic graphic says 65% to 70% of CLABSIs may be preventable with evidence-based practices.

65% to 70% of CLABSIs

may be preventable with evidence-based practices4

Experience SorbaView SHIELD for yourself: Request a sample

Simply complete this form and a Medline representative will contact you to coordinate your no-cost sample.

* Indicates required field

VASCULAR ACCESS HEALTH solution

Make CLABSI prevention second nature

Help improve outcomes and sustain a culture of safety throughout your organization with our comprehensive solution including vascular access best practices, education and training, and a system of products tailored to your needs.

References:

  1. Khong C, Baggs, J, Kleinbaum D, Cochran R, Jernigan JA. The likelihood of hospital readmission among patients with hospital-onset central line-associated bloodstream infections. Infect Control Hosp Epidemiol. 2015; 36(8): 886–892. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4702248/. Accessed June 9, 2021.
  2. Agency for Healthcare Research and Quality. Eliminating CLABSI, A National Patient Safety Imperative: Final Report Companion Guide. Available at: https://www.ahrq.gov/hai/cusp/clabsi-final-companion/clabsicomp4c.html. Accessed June 9, 2021.
  3. Gorski LA et al. Infusion Therapy Standards of Practice. Journal of Infusion Nursing. 2021; 44(15). Available at: https://gavecelt.it/nuovo/sites/default/files/uploads/Infusion Therapy Standards of Practice 2021.pdf. Accessed June 9, 2021.
  4. The Joint Commission. Preventing Central Line-Associated Bloodstream Infections: A Global Challenge, A Global Perspective. Available at: https://www.jointcommission.org/assets/1/18/CLABSI_Monograph.pdf Accessed June 9, 2021.